Evidence map›Paper›PMID 28444738›Full record

ArticleBritish journal of pharmacology2017

Factors influencing biased agonism in recombinant cells expressing the human α

Edilson Dantas da Silva Junior, Masaaki Sato, Jon Merlin, Natalie Broxton, Dana S Hutchinson, Sabatino Ventura, Bronwyn A Evans, Roger J Summers

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. αPharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Functional characterization of the αFrontiers in pharmacology · 2025
    Article
  3. Review
  4. Review
  5. αInternational journal of molecular sciences · 2023
    Review
  6. Characterization of a novel positive allosteric modulator of the αCurrent research in pharmacology and drug discovery · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.International journal of molecular sciences · 2021
    Review
  13. αJournal of receptor and signal transduction research · 2021
    Article
  14. Current Developments on the Role of αFrontiers in cell and developmental biology · 2021
    Review
  15. αFrontiers in pharmacology · 2020
    Review
  16. Updates in the function and regulation of αBritish journal of pharmacology · 2019
    Review
  17. What makes the αBritish journal of pharmacology · 2019
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Edilson Dantas da Silva JuniorDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Masaaki SatoDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Jon MerlinDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Natalie BroxtonDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Dana S HutchinsonDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Sabatino VenturaDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Bronwyn A EvansDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Roger J SummersDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-8367-4056
Discovery Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeAgonists acting at GPCRs promote biased signalling via Gα or Gβγ subunits, GPCR kinases and β-arrestins. Since the demonstration of biased agonism has implications for drug discovery, it is essential to consider confounding factors contributing to bias. We have examined bias at human α EXPERIMENTAL APPROACH: Intracellular Ca KEY

resultsNoradrenaline, phenylephrine, methoxamine and A61603 increased Ca CONCLUSION AND IMPLICATIONS: We have shown that while adrenergic agonists display bias at human α

Indexed as

Adrenergic alpha-1 Receptor AgonistsAnimalsCells, CulturedCHO CellsCricetulusDose-Response Relationship, DrugHumansImidazolesMethoxamineNorepinephrinePhenylephrineReceptors, Adrenergic, alpha-1Structure-Activity RelationshipTetrahydronaphthalenesA 61603Adrenergic alpha-1 Receptor AgonistsImidazolesMethoxamineNorepinephrinePhenylephrineReceptors, Adrenergic, alpha-1Tetrahydronaphthalenes

Identifiers

PMID28444738
PMCPMC5481649
OpenAlexW2609776494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.